- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jason Spangler on Enhancing Equity in Health Technology Assessment
On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research on equity challenges within health technology assessment.
On this episode of Managed Care Cast, we're talking with Jason Spangler, MD, MPH, CEO of the Center for Innovation and Value Research, formerly known as the Innovation and Value Initiative (IVI).
We discuss the strengths and limitations of health technology assessment (HTA), one major limitation being its lack of equity. We also touch on IVI's recent rebrand to the Center for Innovation and Value Research on July 16 and how people can get involved.
Listen above or on one of these podcast services:
Digital Health Implementation Among Older Adults: Health Technology Navigators’ Perspectives
May 14th 2025Health technology navigators share perspectives on barriers to and facilitators of digital health access for older, linguistically diverse patients in a Los Angeles safety-net system.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Trump Administration Walks Back Mental Health Parity in Insurance Coverage
May 13th 2025The Trump administration has decided to further debate the federal rule passed during the Biden administration that guaranteed insurance coverage for treatment of mental illness and substance abuse.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
